Replimune Group (NASDAQ:REPL) Shares Up 5.2% – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL) traded up 5.2% on Tuesday . The company traded as high as $15.24 and last traded at $15.3970. 473,161 shares were traded during trading, a decline of 90% from the average daily volume of 4,979,744 shares. The stock had previously closed at $14.63.

Analyst Ratings Changes

A number of research firms recently commented on REPL. Wolfe Research upgraded shares of Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $11.00 to $17.00 in a research report on Tuesday, August 4th. Weiss Ratings lowered Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Finally, Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price for the company in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.86.

Replimune Group Price Performance

The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -4.88 and a beta of 0.88. The company has a 50 day simple moving average of $10.77 and a 200-day simple moving average of $7.84. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Research analysts expect that Replimune Group, Inc. will post -2.7 EPS for the current year.

Insider Activity at Replimune Group

In other news, insider Konstantinos Xynos sold 11,447 shares of Replimune Group stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $148,467.59. Following the sale, the insider directly owned 224,215 shares in the company, valued at $2,908,068.55. This trade represents a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $510,252.77. Following the completion of the sale, the chief executive officer directly owned 708,151 shares in the company, valued at approximately $9,184,718.47. This represents a 5.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 81,868 shares of company stock worth $1,017,068. 5.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

Large investors have recently modified their holdings of the business. Quantinno Capital Management LP increased its position in shares of Replimune Group by 782.7% in the first quarter. Quantinno Capital Management LP now owns 108,477 shares of the company’s stock valued at $830,000 after acquiring an additional 96,188 shares during the last quarter. EcoR1 Capital LLC acquired a new position in Replimune Group during the first quarter valued at approximately $7,650,000. Seven Fleet Capital Management LP bought a new position in Replimune Group in the first quarter valued at approximately $921,000. Candriam S.C.A. acquired a new position in shares of Replimune Group during the 1st quarter worth approximately $3,014,000. Finally, Jefferies Financial Group Inc. acquired a new position in shares of Replimune Group during the 4th quarter worth approximately $6,942,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.